Lantheus Holdings announces divestiture of its Canadian radiopharmacy operations and commencement of long-term supply agreement

Lantheus Holdings, Inc. announced the sale of its radiopharmacies and Gludef® (Fludeoxyglucose F18 Injection) manufacturing and distribution business in Canada to Isologic Innovative Radiopharmaceuticals Ltd. for $9.0 million US in cash, subject to certain purchase price adjustments. As part of the transaction, Lantheus Holdings and Isologic also entered into a long-term supply contract under which Lantheus Holdings, Inc. will supply Isologic with its products on commercial terms and under which Isologic has agreed to certain product purchase commitments. The transaction included three radiopharmacies owned by Lantheus in Dorval, Quebec, Quebec City, Quebec and Mississauga, Ontario and one radiopharmacy operated by Lantheus in Vancouver, British Columbia. These radiopharmacies prepare individual, patient-ready doses of radiopharmaceuticals that are sold to healthcare providers, which administer those unit doses to patients. The long-term supply contract ensures that Lantheus’ products will continue to be available in the unit dose distribution channel. Fasken Martineau assisted Lantheus Holdings Inc.’s internal legal department with a team that was led by Sylvie Bourdeau (private M&A) and included Marie-Eve Clavet and Guillaume Saliah (private M&A), Anthony F. Baldanza (competition), Alain Ranger (tax), Ingrid VanderElst and Jean-Raphaël Champagne (regulatory), Marc Ouellet and Sébastien Lorquet (labor).